Cystic Fibrosis Newborn Screening: Cost Trajectory as a Marker to Improve Health Outcomes

Pediatric Pulmonology · Published 2026-07-01 · DOI 10.1002/ppul.71747

Free full text

Authors (2)

Ambika Shenoy, Kevin Southern

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Shenoy, A., Southern, K. (2026). Cystic Fibrosis Newborn Screening: Cost Trajectory as a Marker to Improve Health Outcomes. Pediatric Pulmonology. https://doi.org/10.1002/ppul.71747

Related articles

• TAP1 Deficiency Mimicking Primary Ciliary Dyskinesia in a Child With Recurrent Sinopulmonary Infections: A Case Report · Pediatric Pulmonology · 2026 · Same journal
• Volumetric Capnography for Assessing Pre‐ and Post‐Operative Intrapulmonary Shunt in Congenital Pulmonary Lymphangiectasia: A Case Report · Pediatric Pulmonology · 2026 · Same journal
• Comment on “Early Life Food Desert Status Is Associated With Alpha and Gamma Tocopherol Levels and Infant Lung Function” · Pediatric Pulmonology · 2026 · Same journal
• Agreement of Diaphragmatic Excursion Between Anterior Subcostal and Posterior Subcostal Ultrasonography in Premature Neonates · Pediatric Pulmonology · 2026 · Same journal
• Bronchodilator Responsiveness in Preterm‐Born Children With Chronic Lung Disease: Importance of Individualized Testing · Pediatric Pulmonology · 2026 · Same journal
• Performance Evaluation of a Novel Cystic Fibrosis Caregiver Burden Measure Demonstrates Significant Challenges for Parents of Children With CF During the Early Years: The Irish Comparative Outcomes Study (ICOS) · Pediatric Pulmonology · 2026 · Same journal
• Administrative Prevalence and Healthcare Utilization of Pediatric Cystic Fibrosis in a Middle‐Income Country: A 10‐Year Analysis of National Administrative Data · Pediatric Pulmonology · 2026 · Same journal
• Respiratory Outcomes in Children With Neonatal Respiratory Distress Syndrome and Monoallelic ABCA3 Variants · Pediatric Pulmonology · 2026 · Same journal
• Real‐World Clinical Outcomes of Lumacaftor‐Ivacaftor or Tezacaftor‐Ivacaftor Therapy in Children With Cystic Fibrosis Homozygous for Phe508del · Pediatric Pulmonology · 2026 · Same journal
• Impact of Elexacaftor/Tezacaftor/Ivacaftor on Systemic Antibiotic Utilization in Pediatric Patients With Cystic Fibrosis · Pediatric Pulmonology · 2026 · Same journal